U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C13H26N2O4
Molecular Weight 274.3565
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TYBAMATE

SMILES

CCCCNC(=O)OCC(C)(CCC)COC(N)=O

InChI

InChIKey=PRBORDFJHHAISJ-UHFFFAOYSA-N
InChI=1S/C13H26N2O4/c1-4-6-8-15-12(17)19-10-13(3,7-5-2)9-18-11(14)16/h4-10H2,1-3H3,(H2,14,16)(H,15,17)

HIDE SMILES / InChI
Molecular Formula C13H26N2O4
Molecular Weight 274.3565
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Tybamate is a minor tranquilizer that is chemically and pharmacologically related to meprobamate. It is useful in treating anxiety and tension associated with psychoneurotic disorders.

CNS Activity

Originator

Approval Year

1965
159
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
Solacen

Approved Use

Anxiolytic

Launch Date

1964
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
10 μg/mL
EXPERIMENT
https://www.sciencedirect.com/science/article/pii/S0099542808600258
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TYBAMATE serum
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3 h
EXPERIMENT
https://www.sciencedirect.com/science/article/pii/S0099542808600258
15 mg/kg single, oral
dose: 15 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
TYBAMATE serum
Canis lupus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
350 mg 4 times / day steady, oral
Highest studied dose
Dose: 350 mg, 4 times / day
Route: oral
Route: steady
Dose: 350 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
Health Status: unhealthy
Age Group: 22 - 41 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
Health Status: unhealthy
Age Group: 22 - 41 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Other AEs: Drowsiness, Dizziness...
Other AEs:
Drowsiness (7 patients)
Dizziness (6 patients)
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
750 mg 4 times / day steady, oral
Highest studied dose
Dose: 750 mg, 4 times / day
Route: oral
Route: steady
Dose: 750 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
unhealthy, 49.5 years
Health Status: unhealthy
Age Group: 49.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
Other AEs: Tachycardia, Dry mouth...
Other AEs:
Tachycardia (1 patient)
Dry mouth (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
AEs

AEs

AESignificanceDosePopulation
Dizziness 6 patients
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
Health Status: unhealthy
Age Group: 22 - 41 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Drowsiness 7 patients
350 mg 3 times / day steady, oral
Recommended
Dose: 350 mg, 3 times / day
Route: oral
Route: steady
Dose: 350 mg, 3 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
unhealthy, 22 - 41 years
Health Status: unhealthy
Age Group: 22 - 41 years
Sex: F
Sources:
https://pubmed.ncbi.nlm.nih.gov/4890013/
Dry mouth 1 patient
750 mg 4 times / day steady, oral
Highest studied dose
Dose: 750 mg, 4 times / day
Route: oral
Route: steady
Dose: 750 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
unhealthy, 49.5 years
Health Status: unhealthy
Age Group: 49.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
Tachycardia 1 patient
750 mg 4 times / day steady, oral
Highest studied dose
Dose: 750 mg, 4 times / day
Route: oral
Route: steady
Dose: 750 mg, 4 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
unhealthy, 49.5 years
Health Status: unhealthy
Age Group: 49.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/14138831/
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
DY554377
https://www.001chemical.com/chem/4268-36-4
ABI Chem
AC1L2FWM
Ambinter
Amb22734893
http://www.ambinter.com/reference/22734893
Aurora Fine Chemicals LLC
A17.944.630
http://online.aurorafinechemicals.com/info?ID=A17.944.630
BOC Sciences
4268-36-4
Chemieliva Pharmaceutical Co., Ltd
PBCM1305851
ChemMol
99094824
http://www.chemmol.com/chemmol/99094824.html
Compound Cloud
20266
HongKong Chemhere
SCA31878
LGC Standards
LGCFOR1626.00
https://www.lgcstandards.com/US/en/p/LGCFOR1626.00
Molcore
MC554377
https://www.molcore.com/product/4268-36-4
NCI Plated 2007
172126
NovoSeek
20266
Sigma-Aldrich
PH003059_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/ph003059
Sigma Aldrich
PH003059
Sigma Aldrich
PH003059|ALDRICH
Smolecule
S546095
http://www.smolecule.com/products/s546095
THE BioTek
bt-284464
https://www.thebiotek.com/product/inhibitors/bt-284464
ZINC
ZINC000001692922
http://zinc15.docking.org/substances/ZINC000001692922
ZINC
ZINC000002037958
http://zinc15.docking.org/substances/ZINC000002037958
PubMed

PubMed

TitleDatePubMed
Solacen-tybamate.
1966-12
Evaluation of a new minor tranquilizer: tybamate (Solacen).
1965-12-06
PHARMACOLOGIC PROPERTIES OF A NEW TRANQUILIZING AGENT, 2-METHYL-2-PROPYLTRIMETHYLENE BUTYLCARBAMATE CARBAMATE (TYBAMATE).
1964
TYBAMATE, A NEW TRANQUILIZER.
1963-11

Sample Use Guides

In Vivo Use Guide
The usual dose for adults is 0.75 to 2 gm per day. Daily doses larger than 3 gm should not be used.
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Mon Mar 31 18:02:33 GMT 2025
Edited
by admin
on Mon Mar 31 18:02:33 GMT 2025
Record UNII
3875LLL8M8
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TYBAMATE
HSDB   INN   MI   USAN   WHO-DD  
INN   USAN  
Official Name English
SOLACEN
Preferred Name English
W 713
Code English
Tybamate [WHO-DD]
Common Name English
2-(Hydroxymethyl)-2-methylpentyl butylcarbamate carbamate
Systematic Name English
TYBAMATE [HSDB]
Common Name English
TYBAMATE [MI]
Common Name English
W-713
Code English
NSC-172126
Code English
CARBAMIC ACID, BUTYL-, 2-(((AMINOCARBONYL)OXY)METHYL)-2-METHYLPENTYL ESTER
Common Name English
TYBAMATE [USAN]
Common Name English
tybamate [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29756
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
Code System Code Type Description
DRUG CENTRAL
2783
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
HSDB
3410
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
RXCUI
62178
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY RxNorm
WIKIPEDIA
Tybamate
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
INN
1721
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
ChEMBL
CHEMBL2104816
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
NSC
172126
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
NCI_THESAURUS
C98240
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
EPA CompTox
DTXSID7023728
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
SMS_ID
100000076637
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
EVMPD
SUB11369MIG
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
ECHA (EC/EINECS)
224-254-9
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
CAS
4268-36-4
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
MESH
C100147
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
PUBCHEM
20266
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
MERCK INDEX
m11280
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY Merck Index
FDA UNII
3875LLL8M8
Created by admin on Mon Mar 31 18:02:33 GMT 2025 , Edited by admin on Mon Mar 31 18:02:33 GMT 2025
PRIMARY
Related Record Type Details
Structure of TYBAMATE
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966